Member access

4-Traders Homepage  >  Shares  >  Amex  >  CEL-SCI Corporation       US1508374097

 SummaryNewsCalendarCompanyFinancialsConsensusRevisions 
Company
CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company's lead investigational therapy, Multikine, is being developed as a potential therapeutic agent... 
More about the company
Financials ($)
Sales 2014 0,26 M
EBIT 2014 -24,5 M
Net income 2014 -22,9 M
Debt 2014 -
Yield 2014 -
Sales 2015 0,26 M
EBIT 2015 -26,9 M
Net income 2015 -27,0 M
Debt 2015 -
Yield 2015 -
PER 2014 -
PER 2015
Capi. / Sales 2014 334x
Capi. / Sales 2015 334x
Capitalization 86,8 M
More Financials
Latest news on CEL-SCI CORPORATION
4d ago CEL SCI : NEW STORY CEL-SCI Expands its Global Phase III Immunotherapy Head and ..
4d ago CEL SCI : Expands its Global Phase III Immunotherapy Head and Neck Cancer Trial ..
08/12 CEL-SCI CORPORATION : Potential Payoffs Spur Big Board Biotech Action
08/08 CEL SCI : NEW STORY CEL-SCI Corporation Reports Third Quarter Fiscal 2014 Financ..
08/08 CEL SCI : Reports Third Quarter Fiscal 2014 Financial Results
08/08 CEL-SCI CORPORATION : Small companies lead the I-O class of Cancer Therapies
08/01 CEL SCI : NEW STORY CEL-SCI Achieves Milestone in July with Total of 232 Patient..
08/01 CEL SCI : Achieves Milestone in July with Total of 232 Patients Enrolled to Date..
07/30 CEL SCI : NEW STORY France Becomes 17th Country to Clear CEL-SCI for Patient Enr..
07/30 CEL SCI : France Becomes 17th Country to Clear CEL-SCI for Patient Enrollment in..
07/23 CEL SCI : Submission of Matters to a Vote of Security Holders (form 8-K)
07/23 CEL-SCI Has Been Cleared to Begin Patient Enrollment
More news
Comments 
Advertisement
Income Statement Evolution
CEL-SCI Corporation : Income Statement Evolution
More Financials
EPS Revisions
CEL-SCI Corporation : EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF